Advertisement

Topics

Harpoon Therapeutics, Inc. Company Profile

15:53 EDT 25th June 2019 | BioPortfolio

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel T-cell recruiting drug discovery platform called TriTAC (tri-specific T-cell activating construct) to unleash the targeted cell-killing properties of a patient's own immune system through T-cell activation. This approach is being optimized to penetrate tissues and extend serum exposure, and has the potential to address a broad range of cancers, including solid tumors, and immunologic diseases. HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC biologic, is in development for the treatment of prostate cancer and is expected to enter a clinical trial in 2018. For more information, please visit www.harpoontx.com.


News Articles [916 Associated News Articles listed on BioPortfolio]

Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO

Harpoon Therapeutics has filed registration statement with the US Securities and Exchange Commission relating to a proposed underwritten initial public offering.

Harpoon’s IPO Spears $76M as Prostate Cancer Drug Continues Testing

Cancer immunotherapy developer Harpoon Therapeutics is the latest biotech to enter the public markets, raising approximately $76 million in an initial public offering. South San Francisco, CA-based Ha...

IPO raises $75.6M for Harpoon

An initial public offering pulled in $75.6 million for Harpoon Therapeutics, which develops tri-specific T-cell activating co -More- 

Arix Bioscience plc: Harpoon Announces Proposed Public Offering in the United States

Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its portfolio company Harpoon Therapeutics, Inc. ("Harpoon") Rea...

At the Eleventh Hour, Harpoon Therapeutics Signs up to Join the 2018 IPO Game

Harpoon initiated a Phase I trial for its lead candidate for prostate cancer earlier this summer.

Harpoon seeks to raise $86.3M in IPO

Harpoon Therapeutics filed an initial public offering seeking to raise $86.3 million.  -More- 

Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, a New ...

Harpoon’s Third Product Candidate is Slated for Clinical Development in 2019 Read more...

Harpoon Therapeutics nets $70mm via initial public offering

Harpoon Therapeutics Inc. (cancer immunotherapies) completed its initial public offering, netted $70mm through the sale of 5.4mm common shares at $14 (the midpoint of its intended $13-15 range).

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [442 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Clinical Trials [180 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1342 Associated Companies listed on BioPortfolio]

Harpoon Therapeutics, Inc.

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is f...

Maverick Therapeutics Inc.

Maverick Therapeutics is pioneering the next generation of redirected T cell therapeutics in immuno-oncology. Maverick’s highly innovative platform is designed to deliver pot...

Harpoon Medical

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Harpoon Therapeutics, Inc." on BioPortfolio

We have published hundreds of Harpoon Therapeutics, Inc. news stories on BioPortfolio along with dozens of Harpoon Therapeutics, Inc. Clinical Trials and PubMed Articles about Harpoon Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Harpoon Therapeutics, Inc. Companies in our database. You can also find out about relevant Harpoon Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record